Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials: Correction
- PMID: 35849476
- DOI: 10.1097/AOG.0000000000004858
Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials: Correction
Erratum for
-
Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials.Obstet Gynecol. 2022 Jun 1;139(6):1070-1081. doi: 10.1097/AOG.0000000000004787. Epub 2022 May 2. Obstet Gynecol. 2022. PMID: 35675604 Clinical Trial.
References
REFERENCE
-
- Stewart EA, Lukes AS, Venturella R, Arjona Ferreira JC, Li Y, Hunsche E, et al. Relugolix combination therapy for uterine leiomyoma–associated pain in the LIBERTY randomized trials. Obstet Gynecol 2022;139:1070–81. doi:10.1097/AOG.0000000000004787 - DOI
Publication types
LinkOut - more resources
Full Text Sources